Circulating glucagon-like peptide-1 level in patients with liver cirrhosis.
Cirrhosis
chronic liver disease
glucagon-like peptide-1
incretin
Journal
Archives of physiology and biochemistry
ISSN: 1744-4160
Titre abrégé: Arch Physiol Biochem
Pays: England
ID NLM: 9510153
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
pubmed:
13
10
2020
medline:
22
3
2023
entrez:
12
10
2020
Statut:
ppublish
Résumé
Glucagon-like peptide-1 (GLP-1), a gut-derived incretin hormone, plays a pivotal role in glucose-induced insulin secretion. Currently, the role of incretin hormones in the pathogenesis of cirrhosis is not clearly defined. This study aimed to investigate circulating levels of GLP-1 in liver cirrhosis and its association with the severity of liver disease. A total of 80 participants including 39 patients with a definite diagnosis of liver cirrhosis and 41 healthy controls recruited in this cross-sectional study. Circulating levels of GLP-1 were determined using the ELISA method. The severity of liver cirrhosis was assessed according to the Child-Pugh, MELD (i), MELD-Na, MELD New, and UK end-stage liver disease score (UKELD) criteria. The mean age of patients and healthy subjects was 42.51 ± 12.80 and 42.07 ± 10.92 years, respectively ( Larger prospective studies are needed to explore the incretin effect in cirrhosis patients compared with healthy individuals.
Sections du résumé
BACKGROUND
UNASSIGNED
Glucagon-like peptide-1 (GLP-1), a gut-derived incretin hormone, plays a pivotal role in glucose-induced insulin secretion. Currently, the role of incretin hormones in the pathogenesis of cirrhosis is not clearly defined. This study aimed to investigate circulating levels of GLP-1 in liver cirrhosis and its association with the severity of liver disease.
METHODS
UNASSIGNED
A total of 80 participants including 39 patients with a definite diagnosis of liver cirrhosis and 41 healthy controls recruited in this cross-sectional study. Circulating levels of GLP-1 were determined using the ELISA method. The severity of liver cirrhosis was assessed according to the Child-Pugh, MELD (i), MELD-Na, MELD New, and UK end-stage liver disease score (UKELD) criteria.
RESULTS
UNASSIGNED
The mean age of patients and healthy subjects was 42.51 ± 12.80 and 42.07 ± 10.92 years, respectively (
CONCLUSION
UNASSIGNED
Larger prospective studies are needed to explore the incretin effect in cirrhosis patients compared with healthy individuals.
Identifiants
pubmed: 33043692
doi: 10.1080/13813455.2020.1828479
doi:
Substances chimiques
Glucagon-Like Peptide 1
89750-14-1
Incretins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM